Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head …
J Martínez-Trufero, A Lozano Borbalas… - Clinical and …, 2021 - Springer
Abstract Background Sequential treatment of Panitumumab (Pb) plus Paclitaxel (Px) as
induction treatment (IT) followed by concurrent bioradiotherapy (Bio–RT) with Pb may be an …
induction treatment (IT) followed by concurrent bioradiotherapy (Bio–RT) with Pb may be an …
[HTML][HTML] Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell …
Background Panitumumab has the potential to improve the therapeutic ratio of concurrent
chemoradiotherapy for squamous cell carcinoma of the head and neck (SCCHN). Patients …
chemoradiotherapy for squamous cell carcinoma of the head and neck (SCCHN). Patients …
Effect of standard radiotherapy with cisplatin vs accelerated radiotherapy with panitumumab in locoregionally advanced squamous cell head and neck carcinoma: a …
Importance The Canadian Cancer Trials Group study HN. 6 is the largest randomized
clinical trial to date comparing the concurrent administration of anti–epidermal growth factor …
clinical trial to date comparing the concurrent administration of anti–epidermal growth factor …
[HTML][HTML] Phase 2, randomized trial (CONCERT-2) of Panitumumab (PMAB) plus radiotherapy (PRT) compared with chemoradiotherapy (CRT) in patients (PTS) with …
J Giralt, JM Trigo, S Nuyts, EM Ozsahin, K Skladowski… - Annals of …, 2012 - Elsevier
Background We evaluated the safety and efficacy of pmab, a fully human monoclonal
antibody against the epidermal growth factor receptor, by comparing PRT with CRT in pts …
antibody against the epidermal growth factor receptor, by comparing PRT with CRT in pts …
Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study
EDB Morillo, R Mesía, JCA Klain… - Oral …, 2016 - pubmed.ncbi.nlm.nih.gov
Objective To evaluate the activity and safety profile of panitumumab in combination with
paclitaxel in patients with recurrent or metastatic SCCHN. Materials and methods The …
paclitaxel in patients with recurrent or metastatic SCCHN. Materials and methods The …
A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced …
J Giralt, A Fortin, R Mesia, H Minn, M Henke… - 2012 - ascopubs.org
5502 Background: Pmab is a fully human monoclonal antibody against the epidermal
growth factor receptor. We evaluated the safety and efficacy in pts receiving CRT alone or …
growth factor receptor. We evaluated the safety and efficacy in pts receiving CRT alone or …
Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study
E del Barco Morillo, R Mesía, JCA Klain, SV Fernández… - Oral Oncology, 2016 - Elsevier
Objective To evaluate the activity and safety profile of panitumumab in combination with
paclitaxel in patients with recurrent or metastatic SCCHN. Materials and methods The …
paclitaxel in patients with recurrent or metastatic SCCHN. Materials and methods The …
Phase II trial of radiotherapy (RT) with concurrent cisplatin (C) plus panitumumab (pmAb) for patients (pts) with high-risk, resected head and neck cancer (HNC).
RL Ferris, NC Schmitt, DE Heron, JT Johnson, S Kim… - 2014 - ascopubs.org
6090 Background: Treatment intensification for human papillomavirus (HPV)-negative HNC
is an active area of investigation. Targeting the epidermal growth-factor receptor pathway …
is an active area of investigation. Targeting the epidermal growth-factor receptor pathway …
[HTML][HTML] Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer
Addition of panitumumab to adjuvant chemoradiation is tolerable and provides promising
clinical acivity for high risk, resected head and neck squamous cell carcinoma. Background …
clinical acivity for high risk, resected head and neck squamous cell carcinoma. Background …
Demonstrating noninferiority of accelerated radiotherapy with panitumumab vs standard radiotherapy with cisplatin in locoregionally advanced squamous cell head …
D Cheng, K Pak, LJ Wei - JAMA oncology, 2017 - jamanetwork.com
To the EditorSiuandcolleagues1 conductedthelargestclinicaltrial todatetoassessaccelerated-
fractionationradiotherapy (AFX) plus panitumumab compared with standard-fractionation …
fractionationradiotherapy (AFX) plus panitumumab compared with standard-fractionation …
相关搜索
- neck cancer resected head
- cell head neck carcinoma
- cell head standard radiotherapy
- standard radiotherapy neck carcinoma
- neck cancer concurrent cisplatin
- neck cancer high risk
- neck cancer panitumumab in patients
- panitumumab in patients resected head
- radiotherapy in patients head and neck
- radiotherapy in patients cell cancer
- neck cancer trial of radiotherapy
- panitumumab in patients concurrent cisplatin
- panitumumab in patients high risk
- panitumumab pmab trial of radiotherapy
- trial of radiotherapy resected head
- cell head accelerated radiotherapy